VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

NAMUR, Belgium, March 23, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, announced today the closing of its previously announced underwritten public offering of 3,769,231 shares of common stock at a public offering price of $3.25 per share, as well as 565,384 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.  The net proceeds are expected to be approximately $12.8 million, after deducting underwriting discounts, commissions and estimated offering expenses payable by VolitionRx.  All of the shares in the offering were offered by VolitionRx.

Raymond James & Associates, Inc. acted as the sole book-running manager for the offering. National Securities Corporation and Lake Street Capital Markets, LLC acted as co-managers for the offering.

VolitionRx intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes.

The securities described above were issued by VolitionRx pursuant to a "shelf" registration statement on Form S-3 (File No. 333-206781) previously filed with and declared effective by the Securities and Exchange Commission (SEC) on September 18, 2015. A prospectus supplement and an accompanying prospectus relating to the offering was filed with the SEC on March 18, 2016 and are available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway St. Petersburg, FL 33716, or by telephone at (800) 248-8863, or by e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The NuQ® tests are based on the science of Nucleosomics® which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

An animation introducing VolitionRx's Nucleosomics^® technology can be found at: https://www.youtube.com/watch?v=38dodCpyXf0.

Media Contacts
Anita Heward, VolitionRx
[email protected]  
Telephone: +44 (0) 7756 034243

Kirsten Thomas, The Ruth Group
[email protected] 
Telephone: +1 (508) 280-6592

Investor Contacts
Scott Powell, VolitionRx 
[email protected]
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
[email protected]
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "will" and similar expressions identify forward-looking statements, and include statements regarding the anticipated net proceeds of the offering and the intended use of such proceeds.  The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including unanticipated expenses associated with the offering; the Company's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company's development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics® and NuQ® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

SOURCE VolitionRx Ltd